Quantcast
Last updated on April 18, 2014 at 7:49 EDT

Latest BioTrends Research Group Stories

2013-11-21 08:28:22

Surveyed Physicians Expect Nearly 20 Percent of Their Actively Treated HCV Patients to Be On a Newly Approved Regimen, According to a New Report from BioTrends Research Group EXTON, Pa., Nov. 21, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, following the launches of Gilead's sofosbuvir and Janssen/Medivir's simeprevir in the United States, currently marketed triple (Vertex's...

2013-10-31 12:26:44

Surveyed Endocrinologists Indicate a Higher Mean Interest Level for Tresiba versus Dapagliflozin, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 31, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, among surveyed endocrinologists and primary care physicians (PCPs), Janssen Pharmaceuticals' Invokana captures a small percentage of type 2 diabetes patient...

2013-10-31 08:33:35

However, Changes in Treatment Practices Via Improved Originator Biologics Threaten Biosimilar Uptake, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 31, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed U.S. and European oncologists will cautiously adopt biosimilar monoclonal antibodies initially; only a minority of oncologists say they will...

2013-10-30 08:32:29

The New Oral JAK Inhibitor Xeljanz Has Yet to Carve-Out a Distinct Place in the RA Treatment Algorithm, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 30, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. rheumatologists are moderately satisfied with the currently available biologic agents as well as Pfizer's Xeljanz for the treatment of...

2013-10-30 08:32:25

In EU5, Venofer and Sanofi's Ferrlecit/Ferlixit are the Reported Patient Share Leaders in Hemodialysis, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 30, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, while familiarity with FibroGen/Astellas/AstraZeneca's FG-4592/ASP1517 is low among surveyed nephrologists in the EU5 (France, Germany, Italy, Spain...

2013-10-23 08:27:22

Compared with 2012, in Certain Ulcerative Colitis Disease Severities, Remicade Usage Has Decreased Significantly, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 23, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that although the patient share for Janssen's Simponi is low, gastroenterologists report a significant increase in use amongst their...

2013-10-22 12:25:09

More Than Three-Quarters of Non-Prescribers Anticipate Prescribing Tafinlar and Mekinist Within the Next Six Months, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 22, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that at one month post-launch, approximately one-quarter of surveyed U.S. medical oncologists have prescribed GlaxoSmithKline's BRAF-inhibitor...

2013-10-17 08:30:27

Novartis's Lucentis Remains the Most Preferred Intravitreal Pharmacotherapy for Wet AMD Across the EU5, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 17, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, eight months after the approval of Bayer's Eylea for the treatment of wet age-related macular degeneration (AMD), nearly half of surveyed retinal...

2013-10-16 08:27:44

Clinical Results Are Most Influential for Endocrinologists Choosing Between Biosimilars of the Same Reference Brand, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 16, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed U.S. and European endocrinologists require extensive efficacy data from multiple Phase III trials, involving in excess of 1,000...

2013-10-01 12:29:39

Surveyed Nephrologists State that 25 Percent of CKD-ND Patients are Likely Candidates for Recently Approved Injectafer, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 1, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, among surveyed nephrologists, familiarity with Roche's Mircera, is low, but is still second highest among six late-stage renal therapies...